Acta Scientific Cardiovascular System

Research Article Volume 1 Issue 5

Paroxysmal Atrial Fibrillation, Combined Treatment Taking into Account the Correction of Myocardial Oxidative Stress

Rustam G Khabchabov* and Elmira R Makhmudova

"Dagestan State Medical University" of the Ministry of Health of the Russian Federation, Russia

*Corresponding Author: Rustam G Khabchabov, "Dagestan State Medical University" of the Ministry of Health of the Russian Federation, Russia.

Received: September 07, 2022; Published: September 30, 2022

×

Abstract

Background: Structural changes in the myocardium damage the antioxidant barrier of the cardiac conduction pathways, which contributes to the rapid oxidation of one or more ectopic nodes with the development of paroxysmal tachyarrhythmias. To evaluate the effectiveness of the complex treatment of paroxysmal atrial fibrillation and flutter (AF and TP), in comparison with monotherapy of an antiarrhythmic drug of the IC class - propanorm.

Methods: The study involved 63 patients with the first-occurring paroxysmal form of atrial fibrillation and flutter. Patients in the control group underwent standard therapy (propanorm, dabigatran), the study group used complex treatment (propanorm, sodium bicarbonate, Kudesan Q10, solcoseryl, dabigatran).

Results: The study showed; the combined therapeutic effect on the mechanism of atrial fibrillation and flutter with the structural pathology of the atria leads to a significant effect, in comparison with only one antiarrhythmic drug.

Conclusion: This effect is achieved due to additional antioxidant therapy with sodium bicarbonate and Kudesan (Q10), as well as the repository - solcoseryl.

Keywords: Flutter; Atrial Fibrillation; Reparants; Antioxidant Drugs

×

References

  1. Golitsyn SP., et al. “Clinical guidelines for diagnosis and treatment of heart rhythm disturbances and conduction part II”. Cardiological Bulletin3 (2014): 3-52.
  2. Golukhova EZ and Bulaeva NI. “Atrial fibrillation 2014: Based on updated AHA/ACC/HRS recommendations”. Creative Cardiology 4 (2014): 5-13.
  3. Gurevich MA. “Drug therapy of paroxysmal atrial fibrillation”. ru Cardiology 3 (2009): 12-16.
  4. Levchenkova OS and Novikov VE. “Antigipoksanty: possible mechanisms of action and clinical application”. Bulletin of Smolensk State Medical Academy 4 (2011): 43-57.
  5. Martynov AI., et al. “Enhanced use of coenzyme Q10 in patients with cardiovascular diseases”. Eurasian Cardiology Journal 1 (2011): 52-62.
  6. Romanenko VV and Romanenko ZV. “Sudden cardiac death: causes, pathophysiology, diagnosis, treatment, prevention (part 1)”. Medical News 6 (2012): 29-36.
  7. Khabchabov RG., et al. “Combined treatment of paroxysmal forms of atrial fibrillation and flutter taking into account the mechanism of their development”. Bulletin of New Medical Technologies. Electronic edition 5 (2018): 35-41.
  8. Shubik YuV and Tatarsky BA. “Correction of tissue metabolism of solcoseryl in the treatment of ventricular extrasystoles of high gradation according to B. Lown”. Arrhythmology Bulletin 7 (1998): 74-76.
  9. El-Sherif N., et al. “Ventricular arrhythmiasin the late myocardial infarction period in the dog. Epicardial mapping freen trant circuits”. Circulation Research 49 (2005): 255-265.
  10. Lee ID., et al. “Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease”. Nature 519 (2015): 472-547.
  11. Khabchabov RG and Maknmudova ER. “Antiarrhythmic effect of antioxidants in patients with atrial fibrillation”. Journal of Atrial Fibrillation6 (2016): 40-44.
×

Citation

Citation: Rustam G Khabchabov and Elmira R Makhmudova. “Paroxysmal Atrial Fibrillation, Combined Treatment Taking into Account the Correction of Myocardial Oxidative Stress". Acta Scientific Cardiovascular System 1.5 (2022): 19-25.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US